Stockwinners Market Radar for June 22, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Cathie Wood's ARK Investment bought 40.8K shares of TuSimple today

19:01 EDT MediciNova announces MN-001 research collaboration with Juntendo University - MediciNova announced that it will initiate a comprehensive research collaboration with Juntendo University, School of Medicine to evaluate the mechanism of the action of MN-001 on lipid metabolism and metabolic syndrome. The lead collaborator is Takashi Mitsui MD, Ph.D., professor and the chair of the Department of Laboratory Medicine, a known leading expert on lipid metabolism who specializes in dyslipidemia and metabolic syndrome. Kazuko Matsuda, MD, Ph.D., MPH, Chief Medical Officer of MediciNova, Inc, commented, "MN 001 is a novel orally-administered compound with multiple mechanisms, and its anti-fibrotic and anti-inflammatory effects have been observed in multiple animal models studies. It has also been observed to reduce serum triglyceride levels for patients with high serum triglycerides in multiple clinical trials conducted previously. In the phase 2 trial in NASH/NAFLD patients with hypertriglyceridemia, MN-001 (tipelukast) reduced serum triglycerides, increased high-density lipoproteins (HDL-C), and reduced low-density lipoproteins (LDL) during the 12-week treatment period. Furthermore, the improvements in the serum lipid profile were more significant in the patients with type 2 diabetes/prediabetes. We believe this research collaboration will provide new insights into the mechanism of action of MN-001 in the lipid metabolism and metabolic syndrome field and identify the conditions that would benefit from MN-001 treatment."

18:36 EDT Class action suit against NRx Pharmaceuticals dismissed - NRx Pharmaceuticals announced that on June 13, the plaintiffs in the securities class action lawsuit captioned "Dal Bosco v. NRx Pharmaceuticals, Inc. et al." filed a notice in the U.S. District Court for the District of Delaware voluntarily dismissing the action against NRx Pharmaceuticals and its former officers. The dismissal was made without prejudice.

18:25 EDT Menarini, Radius Health submit NDA to FDA for elacestrant - The Menarini Group and Radius Health announced that Menarini, with support from Radius, has submitted a New Drug Application to the U.S. Food and Drug Administration for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer. As part of the submission, the companies have requested Priority Review with the FDA. If Priority Review is granted, the companies anticipate that the FDA would conduct an 8-month review, incorporating a 6-month priority designation review. The NDA submission is based on positive phase 3 data from the EMERALD study that was previously announced on October 20, 2021. EMERALD met both of its primary endpoints, which were progression-free survival in the overall population and PFS in the estrogen receptor 1 mutation subgroup as compared to standard of care with the options of fulvestrant or an aromatase inhibitor.

17:35 EDT Titan International CEO Reitz sells $718K in company shares - Titan International CEO Paul Reitz disclosed in a filing that he had sold 40,000 shares of company stock at $17.95 per share, on June 21, for a total transaction amount of $718,128.

17:30 EDT Apollo, Hostplus partner to launch $1.25B Asia Pacific Credit Strategy - Apollo announced the formation of an Asia Pacific Credit Strategy in strategic partnership with Hostplus, one of the five largest superannuation funds in Australia. The new strategy launches with $1.25B in assets, following an inaugural raise that includes a $500M anchor commitment from Hostplus alongside Apollo's internal and affiliated insurance balance sheets. The dedicated strategy brings Apollo's global credit platform together with local expertise to capitalize on growing demand for private credit across Asia Pacific, providing companies and sponsors with flexible and bespoke solutions. The Asia Pacific Credit Strategy is designed to leverage Apollo's credit expertise and differentiated asset origination to source high-quality opportunities across the yield spectrum. Today, Apollo has more than $10B of assets under management invested in the region and a growing team of nearly 60 investment professionals. Last year, Apollo appointed Partner Matt Michelini as Head of Asia Pacific, now based in Singapore, and hired an Australia-based credit team led by Partner Anthony Hermann, among other key additions. Apollo Co-President Jim Zelter said, "This strategy is a natural extension of our global credit capabilities and reflects growing demand in the region for flexible, expedient capital solutions from non-bank lenders. We are pleased to launch Asia Pacific Credit in alignment with our long-term partners at Hostplus, who share in our disciplined investment philosophy."

17:17 EDT China Pharma receives noncompliance letter from NYSE - China Pharma announced that on June 15, the company received a letter from NYSE American stating that the company was not in compliance with the continued listing standards as set forth in Section 1003 of the NYSE American Company Guide. In order to maintain its listing, the company must submit a plan of compliance by July 15 addressing how it intends to regain compliance with Section 1003 of the company guide by December 15, 2023. If the plan is accepted, the company may be able to continue its listing but will be subject to periodic reviews by the exchange. If the company does not submit a plan or if the plan is not accepted, delisting proceedings may commence. If the plan is accepted but the company is not in compliance with the continued listing standards by December 15 or if the company does not make progress consistent with the plan, the exchange may initiate delisting procedures. The company's management is pursuing options to address the deficiency and intends to submit a compliance plan on or before the deadline set by the Exchange.

17:01 EDT Atkore acquires United Poly Systems - Atkore has acquired United Poly Systems, a manufacturer of High Density Polyethylene pressure pipe and conduit, primarily serving telecom, water infrastructure, renewables, and energy markets. United Poly Systems is the company's fourth acquisition in FY22, and over the past six months, the company has deployed more than $250M dollars towards M&A. United Poly Systems has manufacturing locations in Springfield, Missouri, and Albuquerque, New Mexico with approximately 160 employees. It will continue operating at both locations. United Poly Systems was previously owned by Industrial Opportunity Partners, an operations-focused private equity firm based in Evanston, Illinois.

16:48 EDT Aura Biosciences moves up approximately 6.4% after belzupacap sarotalocan data - Shares of Aura Biosciences moved higher by 84c per share or 6.4% in after-hours trading on Wednesday afternoon to $14 per share after announcing results from a retrospective, matched case control study. This retrospective analysis assessed the visual acuity of patients following treatment with plaque radiotherapy compared with prospective data on visual acuity in subjects with early-stage choroidal melanoma treated with belzupacap sarotalocan by intravitreal administration in the Phase 1b/2 trial, NCT03052127.

16:42 EDT Albertsons says five largest stockholders extend lock-up agreements - In a regulatory filing, Albertsons stated: "On February 28, 2022, Albertsons Companies issued a press release in which its Board of Directors announced that it had commenced a Board-led review of potential strategic alternatives aimed at enhancing the Company's growth and maximizing stockholder value. The review would include an assessment of various balance sheet optimization and capital return strategies, potential strategic or financial transactions and development of other strategic initiatives to complement the company's existing businesses, as well as responding to inquiries. In order to support the company in its continuing evaluation of strategic alternatives, on June 21, 2022, entities affiliated with the company's five largest stockholders, Cerberus Capital Management, L.P., Kimco Realty Corporation, Klaff Realty, L.P., Lubert-Adler Partners and Jubilee Limited Partnership, who are each party to the lock-up agreement dated June 25, 2020, entered into an agreement, pursuant to which each Sponsor agreed to restrictions on its ability to sell or transfer shares of the company's Class A Common Stock that it owns beyond the expiration of the 2020 Lock-Up Agreement through September 10, 2022, the end of the Company's second fiscal quarter. The Extended Lock-Up Agreement supersedes the 2020 Lock-Up Agreement, which was due to expire on June 30, 2022. Under the terms of the Extended Lock-Up Agreement, each Sponsor agrees during the Extended Lock-Up Period, subject to certain exceptions set forth in the Extended Lock-Up Agreement, to not offer, sell, transfer, contract to sell, pledge or otherwise dispose of any shares of Common Stock that the Sponsor directly or beneficially owns as of the Effective Date. The Sponsors beneficially own, in the aggregate, 366,043,040 shares of Common Stock as of the Effective Date or approximately 87% of the shares that were subject to the 2020 Lock-Up Agreement."

16:36 EDT Summit Therapeutics approves $100M rights offering - Summit Therapeutics has approved a rights offering available to all holders of record of the company's common stock, par value 1c as of the close of the market on July 5, the record date. The company intends to distribute to all holders of common stock as of the record date non-transferable subscription rights to purchase shares of common stock at a price per share equal to the lesser of $1.08 per share - the closing price of the Common Stock on June 22 -, or the volume weighted-average price of the common stock for the five consecutive trading days through and including the expiration date of the offering, currently contemplated to be August 5. Assuming that the rights offering is fully subscribed, the company will receive gross proceeds of up to $100M, less expenses related to the rights offering. CEO Robert Duggan, the beneficial owner of approximately 70% of Summit's common stock prior to this rights offering, and COO Maky Zanganeh, a member of the board and the beneficial owner of approximately 6.5% of the company's common stock prior to this rights offering, intend to participate in the rights offering, but have not indicated a minimum level of participation or made any formal binding commitment to participate.

16:31 EDT Kaman invests $10M in Near Earth Autonomy - Kaman has invested $10 million in Pittsburgh, PA based Near Earth Autonomy in exchange for a minority interest in the outstanding equity of Near Earth and one seat on its board of directors. The investment by Kaman will allow Near Earth to accelerate its technology to establish an industry standard in autonomous solutions for the next generation of aviation. This partnership also leverages Kaman's core competency in precision parts manufacturing as the preferred manufacturer of autonomous parts and components for Near Earth. Since 2019, Near Earth has been a partner of Kaman on the autonomy technology for Kaman's K-MAX TITAN heavy-lift optionally piloted helicopter for the United States Marine Corps and the KARGO UAV unmanned aerial system.

16:15 EDT Porch Group prevails on all counts in Kandela vs. Porch.com - Porch Group announced it had prevailed on all counts in the matter of Kandela, v. Porch.com . The presiding arbitrator has also determined that Porch, as the prevailing party, is entitled to reimbursement of its legal costs and expenses. The arbitral tribunal's decision is anticipated to be final and unappealable. In the dispute filed several years ago, owners and managing members of Kandel at such time filed a complaint against Porch.com in the Superior Court of the State of California, alleging breach of contract and other claims related to Porch's acquisition of the Kandela business, which included an earnout provision. The case was transferred to JAMS arbitration pursuant to the terms of the acquisition agreement. "We are pleased with the arbitrator's decision and are happy to have this matter and any related uncertainty behind us," said Matt Ehrlichman, Founder, Chairman and CEO of Porch Group.

16:13 EDT 180 Life Sciences: Goal is to develop TNF therapy for major unmet medical need - 180 Life Sciences released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody: "After our press release press of last week, which included a synopsis of the letters received from the UK Medicine and Healthcare products Regulatory Agency MHRA and the US Food and Drug Administration FDA, we received numerous requests from our stockholders to clarify our plans at 180 Life Sciences for developing a novel therapy for patients with early-stage Dupuytren's disease and I would like to take this opportunity to bring you up to date.Our overall aim continues to be to develop new, patented uses for anti-tumor necrosis factor TNF therapy for major unmet medical needs. To achieve this, we plan to: Perform innovative "translational" clinical research to improve medical care for important unmet medical needs; and Execute on our business objectives to bring beneficial therapies to patients, and thus deliver value for our investors...Early-stage Dupuytren's disease DD affects millions of patients in the US and Europe and for which there is currently no approved therapy... A problem to overcome when aiming to fulfil unmet needs is the need to design new trials for conditions where there are no previously validated endpoints. Our endpoints for early-stage Dupuytren's disease, nodule hardness and size, were selected so as to obtain quantitative information in a reasonable timeframe, i.e., 1-2 years, as opposed to a trial that followed patients for a much longer period. Our trial met its primary endpoint, the hardness of the injected nodules and, importantly, also the secondary endpoint of nodule size. These were pre-specified before the clinical trial was started, so there is no 'cherry-picking' of data."

16:12 EDT KB Home reports ending backlog value up 43% at $6.12B - The company states: "Ending backlog value grew 43% to $6.12 billion, the highest second-quarter level in the Company's history, with each of the Company's four regions generating increases ranging from 18% in the West Coast to 98% in the Southeast. Ending backlog grew 23% to 12,331 homes."

16:07 EDT Synopsys sees WhiteHat Security acquisition neutral to FY22 adjusted EPS - Synopsys announced that it has completed the acquisition of WhiteHat Security, a provider of application security Software-as-a-Service. Synopsys paid $330M in cash and expects the acquisition to be roughly neutral to FY22 non-GAAP earnings per share.

16:07 EDT AMD appoints Mathew Hein as chief strategy officer - AMD announced that Mathew Hein is joining the company as chief strategy officer and senior vice president of corporate development, effective June 27. Hein will be responsible for advancing the company's strategy across an expanded market for high-performance and adaptive computing solutions and will work closely with the AMD executive team to accelerate the company's next phase of growth. Hein will report to AMD chair and CEO, Lisa Su. He joins AMD from DBO Partners, where he served as lead advisor to AMD on a number of opportunities.

16:06 EDT ATIF Holdings announces investment in Phoenix Motor - ATIF Holdings (ATIF) is pleased to announce that it has deepened its investments in emerging technology companies with an investment in Phoenix Motor (PEV) an electric drive system and vehicle maker.

16:04 EDT Alpha Tau announces first use of Alpha DaRT to treat prostate cancer patient - Alpha Tau announced that the first patient was treated in a feasibility study evaluating the alpha-radiation cancer therapy Alpha DaRT as a neoadjuvant therapy in patients with prostate cancer in Haifa, Israel. The primary objectives of this study are to assess the feasibility and safety of intratumoral Alpha DaRT source implantation for the treatment of local prostate cancer prior to surgery. Secondary objectives include assessing radiological and pathological objective response rate of the tumor, and changes in quality of life measures. The study can recruit up to 10 patients.

16:00 EDT Lattice Semiconductor set to join Russell 1000 Index - Lattice Semiconductor Corporation announced it will move up to the Russell 1000 Index from the Russell 2000 Index, effective after the U.S. market opens on June 27, according to the FTSE Russell. Sherri Luther, CFO, said, "We are pleased with the move up to the Russell 1000 Index from the Russell 2000 Index and believe it reflects the tremendous progress we have made over the past few years. We are excited about the path we are on, as we continue to build shareholder value."

15:21 EDT FDA updates on efforts to increase supply and availability of infant formula - The U.S. Food and Drug Administration provided an update on the steps it has taken, and will continue to take, to ensure that American consumers have access to safe and nutritious infant formula in the coming weeks and months. In its update, the FDA stated in part: "In the past month, the FDA has issued enforcement discretion letters for the importation of the infant formula products from six countries, with a total estimated quantity of 17 million cans, or about 365 million full-size, 8-ounce bottles. These products have already started to hit the U.S. market and more will appear on store shelves over the coming weeks and months. Consumers should have confidence that the infant formula that is being imported to the U.S. through this process involved a thorough review of the information provided by the companies, including details about the product's nutritional adequacy and safety, microbiological testing results, labeling information, and importantly, details about the manufacturing facility's food safety production practices and inspection history. The FDA takes its responsibility seriously to ensure the foods we eat are safe and meet our rigorous standards for quality and safety - this is particularly true for infant formula. While the FDA Food Safety Modernization Act requires the agency to inspect domestic food facilities at least once every 3 to 5 years, the FDA has a policy of annually inspecting infant formula manufacturers because the products serve as the sole source of nutrition for some of our most vulnerable consumers... The FDA is continuing to work to ensure infants and individuals with medical conditions who rely on certain specialty, amino acid-based and metabolic infant formula products have access to these life-sustaining products. Some of these products have been available on a case-by-case basis from Abbott Nutrition over the last several months because the risk of not having access to them could significantly worsen underlying medical conditions and in some cases pose life-threatening risks... Abbott Nutrition tested certain product lots that Abbott has held in storage since the FDA's Feb. 17 warning and the company's voluntary recall due to concerns that they were manufactured under insanitary conditions. These products have now undergone enhanced batch testing and the company reports none of the batches tested positive for Cronobacter, a bacterium that can cause severe foodborne illness primarily in infants. The enhanced testing provides further safety assurances to those seeking access to these products... Abbott recently announced that recent severe weather and rainfall resulted in flooding in areas of the Sturgis facility on Monday, June 13. While this is an unfortunate setback and a reminder that natural weather events can also cause unforeseen supply chain disruptions, Abbott is working quickly to assess the damage and will be reporting its progress to the agency in the days ahead. We will return to the facility and work closely with Abbott so that the Sturgis facility can restart producing safe and quality formula products as quickly as possible. Making sure that parents and caregivers have access to both safe and available infant formula remains a top priority for the FDA, and our teams are working night and day to help make that happen. Separately, given the overwhelming public interest in the FDA's prior inspections of the Sturgis facility, the FDA is also releasing establishment inspection reports for several previous Abbott inspections. As previously reported, during our 2019 and 2021 inspections, the agency collected and tested samples of finished products. These samples tested negative for pathogens. During these inspections, it was determined the firm had found batches of Cronobacter contaminated finished product and had taken the appropriate action to destroy three batches, two in 2019 and one in 2020, before distribution. Our most recent inspection in January 2022 was a for cause inspection due to consumer complaints of infant illnesses following consumption of infant formula produced at Abbott's Sturgis facility."

14:28 EDT Magnite on watch following WSJ report on Netflix ad partnership considerations - Comcast's (CMCSA) NBCUniversal and Alphabet's (GOOGL) Google have become top contenders to partner with Netflix (NFLX) over the streaming giant's plan to establish an advertising-supported tier of its service, said The Wall Street Journal. Yesterday, AdAge had reported that Netflix could partner with more than one ad tech company to have a more open platform and said that Magnite (MGNI) had emerged as "a key potential supply-side partner." In Wednesday afternoon trading, Magnite shares remain up 11c, or 1%, at $10.46.

13:27 EDT North American rail traffic fell 2.8% for the week ending June 18 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending June 18. For this week, total U.S. weekly rail traffic was 501,207 carloads and intermodal units, down 2.5% compared with the same week last year. Total carloads for the week ending June 18 were 232,921 carloads, up 0.4% compared with the same week in 2021, while U.S. weekly intermodal volume was 268,286 containers and trailers, down 4.9% compared to 2021. Six of the 10 carload commodity groups posted an increase compared with the same week in 2021. They included grain, up 2,411 carloads, to 22,012; nonmetallic minerals, up 860 carloads, to 32,505; and motor vehicles and parts, up 833 carloads, to 13,366. Commodity groups that posted decreases compared with the same week in 2021 included metallic ores and metals, down 2,707 carloads, to 20,915; coal, down 1,539 carloads, to 66,281; and miscellaneous carloads, down 382 carloads, to 8,908.North American rail volume for the week ending June 18, on 12 reporting U.S., Canadian and Mexican railroads totaled 328,846 carloads, down 0.8% compared with the same week last year, and 353,209 intermodal units, down 4.6% compared with last year. Total combined weekly rail traffic in North America was 682,055 carloads and intermodal units, down 2.8%. North American rail volume for the first 24 weeks of 2022 was 16,198,883 carloads and intermodal units, down 3.6% compared with 2021. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:00 EDT Hillstream CEO expects some human data for HSB-1216 by year-end

13:00 EDT Hillstream CEO says at 'forefront' of emerging ferroptosis mechanism of action

12:40 EDT NJ Acting AG announces settlement with Carnival over 2019 data breach - Acting Attorney General Matthew J. Platkin announced that New Jersey is party to an overall $1.25 million settlement with Carnival Cruise Line that resolves a multistate investigation into a data breach that compromised the personal information of approximately 180,000 Carnival employees and customers nationwide. The multistate investigation determined that deficiencies in Carnival's data security program contributed to the breach in violation of state consumer protection and personal information protection laws. The investigation also determined that Carnival did not provide adequate notice of the breach to consumers and regulators. New Jersey will receive approximately $25,097 from the settlement. Overall, Carnival will pay the participating states a total of $1.25 million under the settlement and implement a number of new requirements that will strengthen Carnival's email security and data breach response practices going forward. In March 2020, Carnival publicly reported a data breach in which an unauthorized actor had gained access to certain Carnival employee e-mail accounts. As a result, employee and customer names, addresses, passport numbers, driver's license numbers, payment card information, health information, and a relatively small number of Social Security Numbers were compromised. A total of 3,100 New Jersey residents were impacted. Breach notifications sent to attorneys general offices stated that Carnival first became aware of suspicious email activity in late May of 2019-approximately 10 months before Carnival reported the breach. Under the settlement announced, Carnival has agreed to a series of provisions designed to strengthen its email security and breach response practices going forward. Those include implementation and maintenance of a breach response and notification plan; email security training requirements for employees, including dedicated phishing exercises; password policies and procedures requiring the use of strong, complex passwords, password rotation, and secure password storage; maintenance of enhanced behavior analytics tools to log and monitor potential security events on the company's network; and undergoing an independent information security assessment. In addition to New Jersey, the following states' Attorneys General participated in the settlement: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Montana, North Carolina, Ohio, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Dakota, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. Reference Link

12:01 EDT Interpublic Group, SpringHill Company form joint venture - Interpublic Group and The SpringHill Company, the Emmy award-winning media conglomerate spearheaded by LeBron James and longtime business partner Maverick Carter, announced the formation of a joint venture, IPG x The SpringHill Company. The companies said: "This partnership will bring IPG clients together with The SpringHill Company's community of diverse and influential creators, emerging talent and modern changemakers to create culturally-relevant and purpose-driven content, partnerships, experiences and products that bring to life The SpringHill Company's mission to empower greatness in every individual. IPG's portfolio of creative, media and marketing services specialists will leverage this joint venture to enhance their short- and long-form creative content for brand marketers." Specific terms of the deal were not disclosed.

12:00 EDT Borr Drilling falls -10.8% - Borr Drilling is down -10.8%, or -66c to $5.43.

12:00 EDT Phreesia rises 8.8% - Phreesia is up 8.8%, or $1.84 to $22.86.

12:00 EDT Revlon rises 38.6% - Revlon is up 38.6%, or $2.34 to $8.40.

11:30 EDT BTRS Holdings sees 23%-25% of FY net revenue recognized in Q2 - Sees 25%-27% of FY revenue recognized in Q3, and 27%-29% in Q4. Sees 1H adjusted gross profit and adjusted gross margin below the midpoint, 2H above. Expects Q2 adjusted EBITDA to look like Q1, followed by significant sequential improvement in both Q3 and Q4.

11:28 EDT BTRS Holdings backs FY22 net revenue growth of 28% at the midpoint - Consensus is $166.64M. Sees Fy22 adjusted gross margin 73.5% at the midpoint, and adjusted EBITDA margin (9%) at the midpoint. Mid-term targets include: Net revenue growth 20%-25% excluding M&A, software and payments segment revenue 25%-30%, adjusted gross margin 75%-80%, adjusted EBITDA margin 8%-12%. Comments taken from investor presentation slides.

11:04 EDT OpenTable makes investment, enters strategic partnership with inline - OpenTable and the inline group announced that the two parties have entered into a strategic partnership. inline is a software provider for online reservations, table management system and other productivity tools for restaurants in East Asia. OpenTable diners will soon have the ability to book reservations and order food at some of the most popular restaurants in the region, powered by inline, and inline restaurant customers will gain access to OpenTable's expansive global dining network. OpenTable, via its parent company Booking Holdings, has also made a strategic financial investment in inline, as part of its continued advancement in the tech and restaurant space.

10:42 EDT Voyager Digital says may issue notice of default to Three Arrows Capital - Earlier, Voyager Digital announced its subsidiary, Voyager Digital Holdings, has entered into a definitive agreement with Alameda Ventures related to the previously disclosed credit facility, which it said "is intended to help Voyager meet customer liquidity needs during this dynamic period." VDH entered into a definitive agreement with Alameda for a $200M cash and USDC revolver and a 15,000 BTC revolver. As previously disclosed, the proceeds of the credit facility are intended to be used to safeguard customer assets in light of current market volatility and only if such use is needed. In addition to this facility, as of June 20, Voyager has approximately $152M cash and owned crypto assets on hand, as well as approximately $20M of cash that is restricted for the purchase of USDC, it stated. Voyager concurrently announced that its operating subsidiary, Voyager Digital, LLC, may issue a notice of default to Three Arrows Capital, or "3AC," for failure to repay its loan. Voyager's exposure to 3AC consists of 15,250 BTC and $350M USDC. The company made an initial request for a repayment of $25M USDC by June 24, and subsequently requested repayment of the entire balance of USDC and BTC by June 27, Voyager stated. "Neither of these amounts has been repaid, and failure by 3AC to repay either requested amount by these specified dates will constitute an event of default. Voyager intends to pursue recovery from 3AC and is in discussions with the company's advisors regarding the legal remedies available. The company is unable to assess at this point the amount it will be able to recover from 3AC," Voyager stated.

10:27 EDT Kids2 acquires Summer Infant, terms not disclosed - Kids2 announced the acquisition of Summer Infant. Summer Infant, which includes SwaddleMe, joins the Kids2 Group umbrella of entities, including renowned brands Baby Einstein, Ingenuity, and Bright Starts. The company said, "The acquisition of Summer Infant is synergistic for Kids2. Both companies share similar passion for supporting families and origin stories. Each was started by parents, for parents, and is dedicated to producing innovative solutions that support early-stage parents on their childrearing journey and as their families grow. Together, Kids2 and Summer Infant will maximize their efforts to deliver a comprehensive scope of parenting products, creating tiny wins and building bright futures for all."

10:22 EDT REX American Resources declares 3-for-1 stock split - REX American Resources announced that its Board of Directors has declared a 3-for-1 split of its Common Stock to be effected as a 200 percent Common Stock dividend. The dividend is payable August 5, 2022, to shareholders of record as of the close of business on July 29, 2022. Shareholders will receive two additional shares of Common Stock for every share held on the record date. As a result of the stock split, REX American Resources' outstanding shares of Common Stock will increase from 5,953,975 at present, to approximately 17,861,925 shares. Taking into effect the planned stock split, effective at the close of business on July 29, 2022, the number of shares of Common Stock previously authorized by the Board of Directors for repurchase will be increased by 200 percent to 1,348,239 shares.

10:03 EDT FedEx announces Picture Proof of Delivery for residential deliveries - FedEx Corp. announced it will soon offer Picture Proof of Delivery for express and ground residential deliveries in the U.S. and Canada that are released without a signature. "This is something e-commerce merchants and customers have been asking for, and we are proud to be the first to announce this service will be available to residential customers. Receiving visual confirmation that the package has arrived gives peace of mind to both merchants and consumers, and we are thrilled to give them that confidence," said Brie Carere, Chief Customer Officer, FedEx. Picture Proof of Delivery will be available "soon" to FedEx Delivery Manager users in select markets, followed by a general release in the United States and Canada "in time for the busy holiday shipping season," the company stated.

10:02 EDT UroGen Pharma trading resumes

10:00 EDT Universal Compression falls -10.8% - Universal Compression is down -10.8%, or -$5.01 to $41.48.

10:00 EDT Micro Focus falls -15.3% - Micro Focus is down -15.3%, or -66c to $3.65.

10:00 EDT Scor ADR rises 10.7% - Scor ADR is up 10.7%, or $2.25 to $23.33.

09:57 EDT UroGen Pharma trading halted, volatility trading pause

09:47 EDT Revlon trading resumes

09:47 EDT Universal Compression falls -11.7% - Universal Compression is down -11.7%, or -$5.43 to $41.06.

09:47 EDT Korn/Ferry rises 5.1% - Korn/Ferry is up 5.1%, or $2.77 to $56.60.

09:47 EDT Revlon rises 30.0% - Revlon is up 30.0%, or $1.82 to $7.88.

09:42 EDT Revlon trading halted, volatility trading pause

09:33 EDT JX Luxventure announces $5M share repurchase program - JX Luxventure announced that on June 20, the company's Board of Directors authorized a share repurchase program of up to $5M of the company's common stock from time to time during a 12-month period by Sun "Ice" Lei, CEO of company. On June 17, Jin Xuan Luxury Tourism Digital Technology Co., Ltd., a subsidiary of the company, entered into and executed a Framework Agreement on Strategic Cooperation with Hainan Douxing Cultural Media Co., Ltd., one of the major live stream content providers with over 30 A list live streamers and reaches over 30,000,000 followers in China. Pursuant to the Agreement, Hainan Douxing will sell JX Hainan cross-border merchandise, including cosmetics and skincare products, in the amount up to $30M on the live-stream E-commerce shows hosted by Hainan Douxing.

09:27 EDT 22nd Century supports federal proposal to require less nicotine in cigarettes - 22nd Century Group, Inc. is now selling a 95% reduced nicotine content cigarette compliant with the renewed federal policy initiative to require all cigarettes sold in the U.S. be made minimally or non-addictive. "We are delighted by today's announcement from the Biden Administration, which is great news for adults who smoke and for 22nd Century Group," said John Miller, president of 22nd Century's tobacco programs. "The FDA requiring tobacco companies to reduce the nicotine content in all cigarettes sold in the United States has long been seen as the most powerful tool in the fight to reduce smoking and its grave health effects on citizens. We are excited to pilot sales of the first and only cigarette designed specifically not to create and sustain addiction, but to instead reduce the hold of cigarette addiction on adult smokers. The facts clearly demonstrate that the overwhelming majority of smokers want to quit, but few are able to do so, even after repeated attempts with current smoking cessation therapies or alternative nicotine products. VLN from 22nd Century offers a new approach in this fight - a tobacco cigarette that actually helps adult smokers reduce their nicotine consumption and smoke less. We are hopeful that many will also go on to quit their habit of smoking highly addictive cigarettes entirely."

09:19 EDT Guess uses Matterport digital twins for retail experience - Matterport (MTTR) announced that GUESS?, Inc. (GES) has adopted Matterport digital twins to ensure brand consistency across its stores and create immersive, virtual experiences for its employees, external buyers and wholesale partners. Since 2017, GUESS has used Matterport digital twins, or photorealistic digital replicas of stores, to realize a 200 percent increase in productivity, a 30 percent decrease in travel costs, and a 95 percent reduction in departmental paper and printer ink costs. Additionally, by equipping employees with iPad and the Bigtincan sales enablement solution, GUESS trained and collaborated remotely with staff, engaged partners and wholesale customers, replacing in person store and showroom visits with virtual experiences.

09:18 EDT Freshpet recalls select product due to potential Salmonella contamination - Freshpet announced on June 17 a voluntary recall of a single lot of Freshpet Select Fresh From the Kitchen Home Cooked Chicken Recipe, with sell by date of 10/29/22, due to potential contamination with Salmonella. The company's Freshpet Team had designated this single lot for destruction, but a small portion of the lot was inadvertently shipped to retailers in limited geographic markets in the last two weeks. No other Freshpet products or lot codes are impacted by this recall. To date, Freshpet has received no reports of illness, injury, or adverse reaction. Reference Link

09:16 EDT Warner Music confirms planning begun for CEO succession - In a regulatory filing, Warner Music Group announced that it has begun planning for the succession of the company's Chief Executive Officer and director, Stephen Cooper. The company expects the transition to happen by the end of 2023. Cooper has served as CEO since 2011 and will continue to serve as CEO and director until his replacement is appointed, the filing noted.

09:12 EDT CME Group to launch first-ever TBA futures for mortgage backed securities - CME Group announced it will expand its suite of long-term interest rate products to offer the first-ever 30-Year Uniform Mortgage-Backed Securities TBA futures contracts on October 3, pending regulatory review.

09:09 EDT The Dewey Electronics Corp announces sale of Hill Property in Oakland, NJ - The Dewey Electronics Corporation announced the sale of its Hill Property in Oakland, NJ

09:07 EDT Orlando Police Department deploys Motorola Solutions' 950 APX NEXT radios - The Orlando Police Department announced it is deploying 950 APX NEXT radios from Motorola Solutions. The radios will enhance officer and community safety with resilient and reliable voice communications, as well as everyday access to crucial police applications and databases. "Our department prides itself on being at the forefront of technology," said Chief Orlando Rolon, Orlando Police Department. "The smart applications and enhanced coverage capabilities of the new APX NEXT radios will help our officers perform more effectively and efficiently, enhancing overall officer and community safety. This investment in next-generation technology marks another step forward in our vision for the future of public safety, and we cannot thank the mayor enough for his unwavering support." APX NEXT radios offer advanced capabilities to help officers better protect and serve communities... "We designed APX NEXT after extensive field research and testing, in consultation with law enforcement agencies across the country, to go beyond what was ever expected for a radio," said Daniel Sanchez, Florida territory vice president, Motorola Solutions. "These radios bring critical information directly to officers' fingertips, while still being the trusted mission-critical communications police have always relied upon. The Orlando Police Department's investment in a device that combines mission-critical voice and purpose-built data applications will enhance their public safety communications."

09:06 EDT SS&C partners with Dublin-based Xcentuate - SS&C announced a new partnership in the EMEA and APAC regions with Xcentuate, an international provider of digital productivity and performance solutions to the financial services, agricultural, pharma and public sectors. The partnership follows SS&C's recent acquisition of Blue Prism, a Robotic Process Automation provider. Xcentuate, based in Dublin, Ireland, will serve as a consulting and implementation partner, acting as an extended team to advise, implement, support and deliver complex projects. The partnership aims to enable SS&C to leverage Xcentuate's experience to access new potential customers, take new value propositions to market, develop point solutions to address current market needs, and enhance its specialized professional services to our customers.

09:05 EDT SOS Limited announces planned ADS ratio change - SOS announced that it plans to change the ratio of its American depositary shares from one ADS representing ten Class A ordinary shares to one ADS representing five hundred Class A ordinary shares. There will be no change to the Company's Class A ordinary shares. The effect of the ratio change on the ADS trading price on the New York Stock Exchange is expected to take place at the open of trading on July 6, 2022. ADS holders of record on the effective date will need to surrender their ADS to the depositary bank for cancellation and exchange in connection with the ADS ratio change, with further details to be provided in the notice by the depositary bank. As of the effective date for the ADS ratio change, SOS' ADSs will continue to be traded on the NYSE under the symbol "SOS". No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements will be distributed to the applicable ADS holders by the depositary bank. As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although the Company can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than the ADS price on a proportionate basis.

09:04 EDT Prologis commits to net zero emissions by 2040 - Prologis announced its commitment to achieve net zero emissions across its value chain by 2040. The company has been carbon neutral for its scope 1 and 2 emissions since 2019. Its 2040 goal encompasses scope 1, 2 and 3 emissions and includes several interim targets to support its progress. These include: 1 GW of solar generation capacity by 2025; Carbon neutral construction by 2025; Net zero for operations by 2030.

09:03 EDT Usio announces expansion of board of directors with appointment of Miller - Usio announced the appointment of Michelle Miller to its Board of Directors effective June 22, 2022. Miller will serve as a member of the Company's Audit and Compensation Committees, expanding the size of the Board to six. For the past 13 years, Miller has served as the Senior Vice President of Private Banking and other executive roles for Broadway Bank.

09:02 EDT Zscaler announces new capabilities for Zero Trust Exchange - Zscaler announced newly advanced AI/ML innovations powered by the largest security cloud in the world for unparalleled user protection and digital experience monitoring. The new capabilities further enhance Zscaler's Zero Trust Exchange security platform to enable organizations to implement a Security Service Edge that protects against the most advanced cyberattacks, while delivering an exceptional digital experience to users, and simplifying adoption of a zero trust architecture.

09:02 EDT Digital Ally announces notable order for body-worn cameras from Wyandotte, KS - Digital Ally announced it has received a notable order from the Wyandotte County Sheriff's Office to further bolster its deployment of body-worn cameras. With the help of the Company's subscription payment program, the Wyandotte County Sheriff's Office ordered an additional twenty-three FirstVu Pro body-worn cameras and twenty-three EVO HDs, continuing the recent expansion to their focus on video safety across their patrol units and county jail. "We're proud of our longstanding relationship with the Wyandotte County, KS, Sheriff's Office as we continue to work together to keep officers and the greater Kansas City community safe," said Stan Ross, CEO of Digital Ally. "It's vital that we continue to innovate this critical technology and it's just as important to have great partners like Wyandotte County who work alongside Digital Ally, adopting these new technologies."

09:01 EDT Zscaler announces Posture Control solution - Zscaler announced its new Posture Control solution, designed to give organizations unified Cloud-Native Application Protection Platform functionality tailor-made to secure cloud workloads. Integrated into the Zscaler Zero Trust Exchange, the Posture Control solution enables DevOps and security teams to efficiently prioritize and remediate risks in cloud-native applications earlier in the development lifecycle. The completely agentless solution correlates and prioritizes risks, such as unpatched vulnerabilities in containers and VMs, excessive entitlements and permissions, and cloud service misconfigurations.

08:51 EDT Thoma Bravo completes $10.4B acquisition of Anaplan - Anaplan announced the completion of its acquisition by Thoma Bravo in an all-cash transaction valued at approximately $10.4B. The acquisition was previously announced on March 20, 2022 and approved by Anaplan stockholders at the Special Meeting of Stockholders held on June 21, 2022. Under the terms of the amended merger agreement, Anaplan stockholders will receive $63.75 per share in cash, which represents a premium of approximately 41% to the volume weighted average price of Anaplan's common stock for the five days ending March 18, 2022, the last trading day prior to the date on which Anaplan publicly announced that it had entered into the original merger agreement. With the completion of the acquisition, Anaplan's common stock has ceased trading and will no longer be listed on the New York Stock Exchange. Anaplan also announced that Frank Calderoni is stepping down from his role as Chairman and CEO, and Charles Goodman, an outside advisor to Anaplan, has been appointed Chairman and interim CEO, effective immediately.

08:49 EDT Jupiter Wellness appoints Andy Goren as CMO, John McCoy as VP, R&D - Jupiter Wellness announced that Prof. Andy Goren, MD, and John McCoy, PhD have joined Jupiter Wellness as Chief Medical Officer and Vice President of R&D respectively. Goren was the founder of Applied Biology whose assets have recently been acquired by Jupiter Wellness. McCoy led the research and development team at Applied Biology, Inc. since 2011.

08:48 EDT Solitario announces results of annual meeting - Solitario Zinc announces results of its Annual General Meeting of Shareholders at which holders of 33,396,907 shares of common stock or 51.56% of the total outstanding shares eligible to vote as of the record date were present in person or by proxy. Election of Directors. Seven directors were elected to serve until the next Annual Meeting of Shareholders or until their successors are elected and qualified. Advisory Vote on Executive Compensation. The shareholders approved the compensation of Solitario's named executive officers with 23,328,557 shares voting for, 417,223 shares voting against, and 9,651,127 broker non-votes. Appointment of Auditors. The appointment of Plante Moran PLLC as Solitario's auditors for fiscal year 2022 was ratified with 32,837,362 shares voting for, 215,748 shares voting against, 343,797 shares voting to abstain, and zero broker non-votes.

08:44 EDT Greenlane provides update on plan to generate $30M in liquidity - Greenlane Holdings provided an update on its strategy to generate more than $30 million in liquidity, as part of its previously announced strategic plan to reduce its cost structure, accelerate its path to profitability, and increase liquidity on a non-dilutive basis. As previously announced in March 2022, this strategy to generate $30 million in non-dilutive liquidity entails the following primary components: Securing an asset-based loan to support working capital needs; Selling the Company's headquarters building in Boca Raton, Florida; and, Discontinuing and disposing of non-core and lower-margin inventory. For the past three months, Greenlane has been engaged in an intensive and comprehensive process to select the ideal partner for an asset-based loan that can support its working capital needs. The Company is in negotiations with respect to this loan facility, and expects to execute an agreement by early Q3 2022, which is expected to result in more than $10 million of liquidity. In addition, the Company listed its headquarters building for sale in May 2022 and has garnered significant interest from several buyers amidst a strong Florida commercial real estate market. Given management's decision to move to a hybrid work model, the Company plans to lease the top floor to another tenant until the building is sold. Along with this initiative, the Company is in the process of selling other non-core assets, which if sold together with the building at the sales price anticipated by management, is expected to generate an additional $10 million of liquidity. Finally, the Company is working to sell through its excess & obsolete inventory of lower-margin, non-strategic products, along with reducing the overall level of inventory on hand. In May, the Company commenced its official E&O sales program internally and has since sold more than $1 million of previously reserved E&O inventory. Management anticipates that the proceeds from these E&O sales, combined with a general sell-down of other non-core third-party brand inventory, is expected to generate more than $10 million of liquidity for the Company. In aggregate, the Company believes that it can generate more than $30 million of liquidity on a non-dilutive basis by the end of 2022 if all these measures are successful.

08:41 EDT Shyft Group introduces Red Diamond Aftermarket Solutions brand - Red Diamond Aftermarket Solutions, a new go-to-market brand of The Shyft Group, makes its debut alongside a trio of initial product offerings - Red Diamond RunFlat to safely steer and brake during a tire blowout; Red Diamond Air Booster to keep motorcoach tires at the recommended pressure; and Red Diamond Self-Leveling System to allow for easy leveling of a coach at the touch of a button. With an online store and hundreds of authorized Spartan RV Chassis service centers across the U.S. able to offer Red Diamond, owners can enjoy peace of mind that premium products and services are available, wherever the adventure leads.

08:39 EDT Berkeley Lights to participate at ESCAT meeting - Berkeley Lights announced its participation at the 27th Annual European Society for Animal Cell Technology, being held from June 26 - 29, 2022 at the Lisbon Congress Centre in Lisbon, Portugal. This year's conference, with the motto, "Advanced Cell Technologies: Making Protein, Cell, and Gene Therapies a Reality," is designed to provide scientists, engineers and other specialists access to the latest innovations, advances, tools and equipment in cell technology. At ESCAT, Berkeley Lights will participate in a symposium session focused on accelerating cell line engineering and development. The company will also feature its Beacon platform technology and workflows in booth #39 for attendees to explore with hands-on demonstrations of our Optofluidic technology as well as how to apply the Berkeley Lights Custom Productivity Assay to rapidly select clones that are producing high-quality bispecific molecules.

08:38 EDT GlucoTrack provides development update on GlucoTrack 2.0 - GlucoTrack announced that it has provided an update on the development of GlucoTrack 2.0. In early Q2 the Company completed lab testing of its Gen 2 clinical prototype system. This process included testing of multiple iterations of electronics, ear clip, and mobile app with cloud-based software. In addition, human factors testing of the mobile app has been completed through simulated use in focus groups and by conducting a rigorous external design review for system architecture, stability, and cybersecurity. The completion of bench testing and analyses of the Gen 2 clinical prototype system was followed by simulated use testing. During this in-house testing, the Company achieved better than expected accuracy and performance. Initial data collected indicates that the Gen 2 system may achieve an accuracy comparable to invasive Continuous Glucose Monitors currently available in the market when conducting the upcoming first in-human clinical study. The Company has recently received Ethics Committee and clinical center approvals to conduct this study at the Rabin Medical Center in Israel. The initial results from this study will drive a follow-up multi-center study in the United States, led by Dr. Klonoff, Chair of the Company's Scientific Advisory Board and Medical Director of the Diabetes Research Institute of Mills-Peninsula Medical Center. The U.S. study is intended to be a precursor to the eventual pivotal trial for FDA clearance. The Company aims to begin its first in-human study in Israel in Q3 and in U.S. centers in Q4. In addition, these positive results are driving a design re-assessment that the Company believes will lead to a more user-friendly system with a lower cost and faster measurement time than initially targeted.

08:36 EDT Triton International says CFO John Burns to retire by 2022-end - Triton International Limited announced that John Burns, Senior Vice President and Chief Financial Officer, intends to retire at the end of 2022 after more than 25 years with the Company. Mr. Burns will remain in his role until a successor is in place and following his retirement will serve in an advisory role to ensure a smooth transition. The Company has initiated a search for a successor, which will include both internal and external candidates. Triton has engaged Korn Ferry to assist in its CFO search process.

08:35 EDT Sypris Solutions subsidiary receives multi-year production contract - Sypris Electronics, a subsidiary of Sypris Solutions, announced that it has recently received releases under a new, multi-year production contract that was first announced in February of this year. The order, which provides for Sypris to begin full-rate production beginning in 2022, calls for the manufacture and test of power supplies for an initial five systems to be supplied to a U.S. DOD contractor. Terms of the award were not disclosed. The modules produced by Sypris will be integrated into an electronic warfare improvement program for the U.S. Navy. According to news sources, the upgrade will provide the capability to actively jam incoming missiles that threaten a warship, cue decoys and adapt quickly to evolving threats. The improvements to the electronic attack portion will provide integrated countermeasures against radio frequency-guided threats and extended frequency range coverage according to the U.S. Navy. The system's capability for non-kinetic electronic attack options can be further deployed in additional critical areas. From advanced communications to multi-role waveforms, the multi-function applications of the system will provide enhanced mission capabilities to the U.S. Navy Fleet while presenting opportunities for future reductions in cost, size, weight, and power according to the U.S. Naval Institute.

08:35 EDT Athenex sells revenues from US, European royalty, milestone interest in Klisyri - Athenex announced the signing of a definitive agreement for the sale of revenues from U.S. and European royalty and milestone interests in Klisyri to Sagard Healthcare Partners and funds managed by Oaktree Capital Management for $85M. Approximately $80M of the proceeds from the transaction will be used toward partially paying down existing debt and operating the business, with $5M to be placed into escrow and paid to Athenex upon the satisfaction of certain conditions. The transaction is subject to customary closing conditions. "We are executing on our new strategy and will continue to deliver on the objectives that we laid out to extend our cash runway by over 18 months. We are pleased to enter into this agreement, as we believe it generates meaningful benefits for our stockholders as we continue to pay down debt and extend our cash runway," said Dr. Johnson Lau, Chief Executive Officer of Athenex. "The sale of the revenues from the U.S. and European royalty and milestone interests in Klisyri represents another step in continuing to monetize non-core assets to focus on developing our potential best-in-class NKT cell platform."

08:32 EDT Golden Path Acquisition's business combination deadline extended to July 24 - Golden Path Acquisition announced that the company's sponsor, Greenland Asset Management, has deposited into the company's trust account an aggregate of $191,667, representing 3.3c per public share of the company, in order to extend the period of time the company has to consummate a business combination by one month to July 24. The sponsor plans to extend such period of time additional eight times to complete its initial business combination as necessary, each by an additional one months, up to March 24, 2023, by depositing $191,667 each time and up to an aggregate amount of $1,533,333 into the Trust Account, representing up to an additional 26.7c per public share, in connection with such additional extensions.

08:32 EDT Perpetua Resources receives first permit for Stibnite Gold Project - Perpetua Resources received the Clean Air Act Permit to Construct for the Stibnite Gold Project from the Idaho Department of Environmental Quality on June 17. The Air Permit mandates compliance with state and federal air standards and regulates emissions from construction and operation of the Project.

08:30 EDT Assembly Biosciences presents new data on ABI-H3733, ABI-4334, vebicorvir - Assembly Biosciences announced data from the company's investigational core inhibitor programs ABI-H3733, ABI-4334 and vebicorvir, featured in six poster presentations at the International Liver Congress, the Annual Meeting of the European Association for the Study of the Liver, EASL, taking place virtually and in London on June 22-26, 2022. Next-Generation HBV Core Inhibitor Candidates 3733 and 4334: The poster entitled "Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities," presents pharmacokinetic data on the new tablet formulation for 3733. In preclinical studies, the T2 formulation at 100 mg dose showed equivalent plasma serum concentration to the liquid formulation. In HBV patients, the 300 mg dose formulated as the new T2 tablet is projected to achieve exposure that is approximately 150- and 29-fold higher than the protein adjusted EC50 for inhibition of HBV DNA replication and cccDNA formation, respectively. In the poster entitled "ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents cccDNA formation by disruption of incoming capsids," preclinical data indicate that 4334 prematurely melts incoming HBV capsids, preventing formation of cccDNA with a single digit nM EC50. These preclinical data also show the compound potently inhibits pgRNA encapsulation resulting in the formation of empty capsid particles, consistent with the activity of Class II core inhibitors. Vebicorvir: "Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment-naive patients with HBeAg positive chronic hepatitis B," provides ad hoc analyses from Assembly Bio's Study 202 in which treatment naive, HBeAg positive patients were randomized in a blinded fashion to receive once a day entecavir either with or without vebicorvir for 24-weeks. As reported previously, addition of VBR to entecavir treatment resulted in statistically significant declines in HBV DNA and pgRNA and normalization of ALT levels compared to entecavir treatment alone. "Greater sequence diversity during early hepatitis B virus decline on vebicorvir plus entecavir is associated with a lower level of virus rebound following switch to entecavir monotherapy" utilizes next-generation sequencing to describe viral diversity from the clinical samples of patients from Study 202 who progressed to receive open-label VBR plus entecavir and subsequently switched to entecavir treatment alone. Viral diversity as well as viral rebound were measured following the switch to monotherapy. "Evaluation of the drug-drug interaction profile of vebicorvir, a first-generation hepatitis B core inhibitor: findings from Phase 1 and Phase 2a studies" describes the potential for VBR to be a perpetrator of drug-drug interactions using CYP index substrates in a Phase 1 study in healthy participants. "Evaluation of the disposition and mass balance recovery of vebicorvir, a first-generation hepatitis B core inhibitor, in rats and humans" shows favorable liver loading and very limited metabolism of VBR in rat studies and that the drug was primarily eliminated as unchanged parent compound in the feces of both rats and humans.

08:25 EDT CN to invest C$430M in Ontario in 2022 - CN announced plans to invest approximately C$430 million in Ontario in 2022. This includes investments in technology, capacity, rolling stock units and company-wide decarbonization initiatives, as well as network improvements. These investments will power sustainable growth and ensure the continued safe movement of goods in Ontario and everywhere on CN's transcontinental network.

08:24 EDT CN to invest C$365M in Alberta in 2022 - CN announced plans to invest approximately C$365 million in Alberta in 2022. This includes investments in technology, capacity, rolling stock units and company-wide decarbonization initiatives, as well as network improvements. These investments will power sustainable growth and ensure the continued safe movement of goods in Alberta and everywhere on CN's transcontinental network.

08:23 EDT Lightbridge announces Massachusetts MIT awarded $800,000 by DOE - Lightbridge Corporation (LTBR) announced that the Massachusetts Institute of Technology, MIT, has been awarded approximately $800,000 by the U.S. Department of Energy's, DOE, Nuclear Energy University Program R&D Awards to study the deployment of Accident Tolerant Fuels in Small Modular Reactors. The project will be funded in its entirety by the DOE, with the goal of bringing collaborative teams together to solve complex problems to advance nuclear technology and understanding. Among other objectives, the project will simulate the fuel and safety performance of Lightbridge Fuel inside a small modular reactor designed by NuScale Power (SMR). Seth Grae, President and CEO of Lightbridge commented, "We are honored to have the opportunity to collaborate with MIT's prestigous Department of Nuclear Science & Engineering in this important study, where MIT will simulate the usage and safety performance of Lightbridge Fuel inside of a NuScale Power small modular reactor. Importantly, this research dovetails with our strategic focus on fueling SMRs of the future and the potential additional benefits Lightbridge Fuel rods will bring to SMRs."

08:20 EDT Pliant Therapeutics presents preclinical data on PLN-101325 - Pliant Therapeutics presented new preclinical data highlighting the potential of PLN-101325, an alpha7beta1 integrin activating antibody for the treatment of muscular dystrophies, including Duchenne Muscular Dystrophy. These data were presented at the New Directions in Biology and Disease of Skeletal Muscle Conference being held June 20-23, 2022 in Fort Lauderdale, Florida. The presentation "Increased Laminin Binding Through Integrin Activation Protects Dystrophic Muscle" was presented by Scott Turner, Ph.D., Senior Vice President, Head of Research at Pliant Therapeutics. It highlighted in vitro and in vivo data demonstrating improved cell morphology, tissue organization and muscle function in human cells and D2-MDX mice after treatment with PLN-101325. Importantly, results showed significant improvements in diaphragm muscle strength and respiratory function. Progressive loss of muscle mass and strength, including respiratory muscle strength, has been observed in muscular dystrophy, contributing to death from respiratory insufficiency. The alpha7beta1 integrin is a laminin receptor located on the muscle cell surface that is upregulated in muscular dystrophy patients, serving as a compensatory muscle stabilization mechanism. Activating the alpha7beta1 integrin may help stabilize the muscle membrane, increase muscle strength, and decrease muscle damage. Because alpha7beta1 can compensate for the loss of the dystroglycan complex, this mechanism has the potential to be combined with existing therapies, as well as those currently in development. Pliant expects to file an Investigational New Drug application on this program by the end of 2022, with an anticipated entry into the clinic in early 2023.

08:18 EDT Zenvia announces changes in corporate structure - Zenvia will be implementing changes in the corporate structure following the accelerated growth of its SaaS business. The company has focused on strengthening its three existing business lines: SaaS, CPaaS, and Consulting to have teams exclusively dedicated to each business line. As a result, Raphael Godoy, former CMO, will become SaaS Chief Revenue Officer, or CRO. Cristiano Franco will be CPaaS CRO, and Luca Bazuro will become the Consulting business line CRO. The Consulting business, resulting from the D1 Smarkio integration, will now support the adoption of Zenvia's SaaS and CPaaS products by the corporate market. Rogerio Perez, former CX Services Executive Director, will now report directly to Raphael Godoy. Shay Chor, current Investor Relations Officer, will become CFO. Mariana Cambiaghi will remain as Finance Executive Director, responsible for accounting, financial controls & processes, and treasury. Laura Hirata remains the General Counsel. Additional ZENVIA's executive team members reporting directly to Cassio Bobsin include Gabriela Vargas, who will become Chief Marketing Officer; Lilian Lima, CTO, responsible for IT and Products; and Katiuscia Teixeira, CHRO, to lead People and Culture areas.

08:16 EDT Rover Group set to join Russell 3000, Russell 2000 Indexes - Rover Group is set to join the broad-market Russell 3000 Index, the small-cap Russell 2000 Index, and the Russell Microcap Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, according to the list of additions posted June 17.

08:15 EDT Lynk & Co selects Cerence to power conversation AI - Cerence Inc. (CRNC) announced that Lynk & Co, a global automotive brand formed as a joint venture between Geely Auto Group (GELYF) and Volvo Car Group (VLVLY), has selected Cerence to provide conversational AI-powered in-car assistant capabilities across its lineup as it continues to expand to Europe. In partnership with ECARX, Geely's tier-one supplier driving the development of the in-car user interface across its brands, Cerence will provide Lynk & Co with automatic speech recognition, natural language understanding and text-to-speech in a variety of languages.

08:13 EDT Tosyali Harsco enters multi-year service contract with Kardemir Steel - Tosyali Harsco, a joint venture between Harsco Envronmental and Tosyal Holding, announced it has successfully entered into a new multi-year services contract with Kardemir Steel. Kardemir is a family-owned steel mill located in zmir, Turkey, producing long products and profiles at three separate facilities. Tosyali Harsco brings to Kardemir its expertise in safe and reliable under furnace digging. Kardemir is a new customer for Tosyali Harsco, and a first contract in the Izmir area in Western Turkey. This reinforces Tosyal Harsco's ambition to grow its footprint in all areas of steelmaking in Turkey. "This Kardemir multi-year service contract is the product of Tosyali Harsco's performance in Turkey and unique offerings in the industry as a provider of environmental solutions and services," said Stephane Boissinot, Director of Operations, Europe South, Eastern Europe, Turkey & SteelPhalt for Harsco Environmental. "Kardemir is an important steel mill in Turkey. We see this contract as the start of a long-term relationship where we can grow and further demonstrate our capabilities in environmental solutions."

08:11 EDT DMG Blockchain Solutions launches Terra Pool - DMG Blockchain Solutions (DMGGF) announces the launch of Terra Pool, a clean, renewable energy Bitcoin mining pool partnership between DMG and Argo Blockchain (ARBK). Testing has concluded and Terra Pool is now open to the general Bitcoin mining public. Terra Pool, developed using DMG's Blockseer technology, is a unique Bitcoin mining pool focused on clean energy as the basis for participation. The pool allows its members to showcase their commitment to clean energy operations and creates new bitcoin from renewable energy sources.

08:10 EDT MEI Pharma announces Anne Frese as Chief People Officer - MEI Pharma announced that Anne Frese, an industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately.

08:09 EDT BioSig enters new evaluation agreement for PURE EP with Cleveland clinic - BioSig Technologies announced it has entered an evaluation agreement for its PURE EP System with the Cleveland Clinic. The evaluation agreement marks the first since BioSig inducted a new commercialization team. Consistent with The Company's stated national rollout strategy, Cleveland Clinic will participate in a 60-day evaluation of BioSig's PURE EP System. The Company recently announced that is has restructured its clinical support and installation teams to streamline and accelerate the pathway from product evaluation to adoption. "We are excited to include Cleveland Clinic as an evaluation center for the Pure EP System. We look forward to working alongside their physicians to demonstrate the superior signal quality that can be achieved on even the most difficult arrhythmias," commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies.

08:08 EDT Cheniere Energy, Chevron sign long-term LNG sale and purchase agreements - Cheniere Energy (LNG) announced that two of its subsidiaries, Sabine Pass Liquefaction, or SPL, and Cheniere Marketing, have each entered into long-term liquefied natural gas, or LNG, sale and purchase agreements with Chevron USA, a wholly-owned subsidiary of Chevron (CVX). At plateau, Chevron will purchase a combined 2M tons per annum, or mtpa, of LNG from Cheniere subsidiaries, subject to certain conditions described below. Under the first SPA, Chevron has agreed to purchase approximately 1.0 mtpa of LNG from SPL on a free-on-board, or FOB, basis. Deliveries under the SPA will begin in 2026, reach the full 1.0 mtpa during 2027 and continue until mid-2042. Under the second SPA, Chevron has agreed to purchase approximately 1.0 mtpa of LNG from Cheniere Marketing on an FOB basis with deliveries beginning in 2027 and continuing for approximately 15 years. The Cheniere Marketing SPA is subject to Cheniere making a positive final investment decision to construct additional liquefaction capacity at the Corpus Christi LNG Terminal beyond the seven-train Corpus Christi Stage III Project. The purchase price for LNG under the SPAs is indexed to the Henry Hub price, plus a fixed liquefaction fee. Additionally, Cheniere's subsidiary, Sabine Pass LNG, L.P. ("SPLNG"), and Chevron have agreed to terms for the early termination of their LNG Terminal Use Agreement (the "TUA") in return for a lump sum payment to be made by Chevron to SPLNG during calendar year 2022. Termination of the TUA is subject to the consent of certain lenders to Cheniere Energy Partners, L.P., expected during the third quarter of 2022.

08:08 EDT Rubius presents updated data from type 1 diabetes program at FOCIS 2022 - Rubius Therapeutics announced updated preclinical data for its type 1 diabetes program at the FOCIS 2022 Annual Meeting in San Francisco, CA, June 21-24, 2022. "Induction of Antigen-Specific Immune Tolerance in Type 1 Diabetes by Antigen-Expressing Re Cell Therapeutics:" Demonstrated tolerance induction and bystander suppression in stringent type 1 diabetes preclinical models; From ongoing experiment, showed efficacy in the NOD preclinical model; By increasing to 3 doses administered and optimizing the dosing schedule, results at 25 weeks exhibit bystander suppression by delivering only two antigens, indicating disease prevention caused by many autoantigens; Previously reported data at 25 weeks with two doses prevented or delayed disease onset; Established efficacy in the BDC2.5 adoptive transfer model with data supporting that repeated dosing extends duration of disease protection, reverses established inflammation, which is important for the treatment of existing autoimmunity, and induces two types of regulatory T cells, resulting in protection against re-challenge; These findings are potentially translatable beyond type 1 diabetes to multiple autoimmune diseases

08:07 EDT Phibro Animal Health, Rejuvenate Bio in pact to develop gene therapy for MVD - Phibro Animal Health Corporation and Rejuvenate Bio announced a collaboration for the development and commercialization of a gene therapy for Mitral Valve Disease, MVD, in canines. The incidence of MVD varies widely but is believed to be present in about 7% of all dogs and can be as high as 80% for some breeds such as Cavalier King Charles Spaniels. Rejuvenate Bio has received support from the American Cavalier King Charles Spaniel Club for this research. MVD is caused by a malfunction of the Mitral Valve which allows blood to flow backward from the heart's lower chamber to the upper chamber. The condition often results in and is diagnosed by a characteristic 'murmur'. The disease may have few or no outward effects at first, but over months or years can progress to congestive heart failure and death. Current therapies have been proven to slow the course of MVD, but no therapy is available to stop the disease or reverse the damage. The objective of the collaboration between Phibro and Rejuvenate Bio is to develop and commercialize a novel gene therapy with the intent to not only stop MVD before it results in heart failure but reverse some or all the damage done to the heart. Thomas Zerzan, President of the Companion Animal Division at Phibro Animal Health, stated, "We have confidence that our collaboration with Rejuvenate Bio will meet our goal to bring about an effective gene therapy that will revolutionize the way veterinarians treat MVD, adding healthy, happy years to the life of a dog who suffers from this disease." Daniel Oliver, CEO of Rejuvenate Bio, stated, "We are excited to work with Phibro to make the treatment of MVD a reality. We expect to file for a conditional approval as early as 2023. We view this as a first step to tackling numerous age-related diseases that affect the animals we love." The effort to develop a gene therapy for MVD is based on research and discoveries made in the lab at Harvard Medical School and the Wyss Institute by genetics scientist and startup founder, George Church.

08:06 EDT Rhythm Pharmaceuticals announces EC authorized variation for IMCIVREE - Rhythm Pharmaceuticals announced that the European Commission, EC, this week authorized a variation for IMCIVREE that allows for dosing in patients with POMC or LEPR deficiency who have mild, moderate or severe renal impairment. "We are pleased the EC has recognized the impact IMCIVREE can have on the lives of patients living with hyperphagia and severe obesity caused by rare MC4R pathway diseases," said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. "The expansion of the dosing regimen to include patients with renal impairment is an important step in ensuring more patients have access to a therapy that addresses the root cause of these rare genetic diseases." The EC's approval of the Company's renal dosing variation allows for patients aged 6 years and older with POMC or LEPR deficiency and with mild, moderate, or severe renal impairment to be treated with IMCIVREE. There are no dose adjustments for patients with mild or moderate renal impairment and a separate dose titration schedule is provided for patients with severe renal impairment.

08:05 EDT Mustang Bio announces FDA granted ODD to MB-106 - Mustang Bio announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to MB-106, Mustang's CD20-targeted, autologous CAR T cell therapy for the treatment of Waldenstrom macroglobulinemia, a rare type of B-cell non-Hodgkin lymphoma. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center to treat patients with relapsed or refractory B-NHLs and chronic lymphocytic leukemia. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, "We are very pleased to receive Orphan Drug Designation from the FDA, as it is an important regulatory milestone for Mustang's MB-106 program for the treatment of Waldenstrom macroglobulinemia, a rare B-NHL with a significant unmet medical need. We look forward to dosing the first patient in our multicenter Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 for relapsed or refractory B-NHL and CLL under Mustang's IND shortly. In the Phase 1 portion of this trial, MB-106 dose escalation will proceed in three separate arms, and Waldenstrom patients will be included in the indolent lymphoma arm in parallel with accrual of patients to the aggressive lymphoma and CLL arms."

08:05 EDT Sono Motors expects to generate further revenues with solar customers - As key milestones in 2022, Sono Motors expects to present series-validation vehicles during a community event this summer and to nominate all series suppliers by the end of the third quarter. In terms of financial guidance for 2022, Sono Motors expects to generate further revenues with solar customers, the vast majority of which are expected for the fourth quarter of 2022.

08:03 EDT Athira Pharma falls 70% after Ph2 study of fosgonimeton did not meet endpoint - Shares of Athira Pharma are down 70% at $2.55 in pre-market trading after the company announced that its topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease did not meeet primary endpoint .

08:02 EDT Rhythm Pharmaceuticals launches IMCIVREE in Germany - Rhythm Pharmaceuticals announced IMCIVREE is now available to patients in Germany. IMCIVREE, a melanocortin-4 receptor agonist, last year received marketing authorization from the European Commission for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1, deficiency or biallelic leptin receptor deficiency in adults and children 6 years old and older. "We are excited to make IMCIVREE available to treat patients in Germany living with the hyperphagia and severe obesity caused by these rare MC4R pathway diseases," said Yann Mazabraud, Executive Vice President, Head of International at Rhythm. "We thank the German authorities for their recognition of the need for a therapy to treat obesity and control hunger due to POMC and LEPR deficiencies as we work to transform the lives of patients living with these diseases."

08:02 EDT Harley-Davidson appoints Tralisa Maraj as CFO of LiveWire - Harley-Davidson appointed Tralisa Maraj as CFO at LiveWire. Maraj formerly served as both CFO & Corporate Secretary for CGX Energy and previously served as Chief Accounting Officer. Prior to CGX, Maraj served as Corporate Controller at Remora Energy Management.

07:59 EDT Revlon up another 29% amid increase in StockTwits message volume - Shares of Revlon are up another 29% at $7.81 per share in pre-market trading following yesterday's gains of 62.5%. The stock is the highest trending name on StockTwits in terms of message volume over the past 24 hours.

07:51 EDT Arch Therapeutics provides update on reimbursement strategy - Arch Therapeutics provided an update regarding its reimbursement strategy for the use of AC5 Advanced Wound System, specifically regarding its use in doctor's offices and wound clinics. This segment represents its third targeted selling channel and is expected to expand upon the Company's first two selling channels: government facilities and non-government hospital operating rooms, which are currently supported by Lovell Government Services and Centurion Therapeutics, respectively. Specific action items related to the Company's reimbursement initiative in doctor's offices and wound clinics include the following: Sunsetting the Pilot Program. The previously announced Pilot Program delivered on its objectives and is set to begin a natural wind-down process as the company transitions to its next stage of the reimbursement life cycle. The Pilot yielded patient data and payor responses across a wide array of healthcare systems, expanded access to multiple providers, generated clinical data, and tested various coding options that, together, helped guide the development of the Company's HCPCS application to request a category specific code for AC5. Leveraging New Temporary Code for Synthetic Skin Substitutes. Effective April 1, 2022, CMS authorized the use of A4100 as a temporary code to facilitate the reimbursement of doctor's offices and wound clinics for the use of synthetic skin substitutes. The Company has begun the process of advising providers to submit claims under this new code as the Company pursues a permanent HCPCS code, as described below. Filing a HCPCS Application. The Company expects to submit its HCPCS application for specific coding to Centers for Medicare and Medicaid Services in the coming weeks. HCPCS is a collection of standardized codes for medical procedures, products and services that facilitate the submission and processing of insurance claims for Medicare and other health insurers. Launching a Multi-Site Clinical Study. Building on the progress of the Pilot program, clinical outcomes, and observations from key opinion leaders, the Company is planning to launch a multi-site clinical study in the third calendar quarter of 2022. The study is expected to enroll and treat up to approximately 60 patients at six sites, with the primary end point of wound closure. This study is intended to accelerate payor adoption as well as differentiate and highlight the key benefits of AC5 in treating hard to heal wounds.

07:38 EDT Ostin begins delivery of large display module orders to Sichuan AI-Chance Tec - Ostin Technology Group announced that the Company has started delivering the display module orders of an aggregate value of RMB 20.64M to Sichuan AI-Chance Tec, a Tier 1 auto electronic components and technology supplier in China. The display modules ordered by AI-Chance will be used to manufacture its in-car screens customized for Chinese electric vehicle manufacturer WM Motor Holdings. The Company expects to complete delivery of all the AI-Chance orders by the end of this year. Tao Ling, Chairman and CEO of the Company commented: "We are delighted to start the delivery of orders to AI-Chance, which are a testament to our products. We are focused on ramping up production to catch up with the increasing demand for display modules due to the expansion of the automotive display market in China."

07:36 EDT Enovix to join Russell 2000, 3000 Indexes - Enovix announced that it is set to be added as a member of the Russell 2000 and 3000 Indexes, effective after the U.S. market opens on June 27, according to a updated membership list of additions posted by FTSE Russell on June 17, 2022.

07:35 EDT OpGen announces 1,000th patient sample enrolled in trial for Unyvero UTI Panel - OpGen reported today that it has enrolled its 1,000th prospective patient sample for its Unyvero Urinary Tract Infection Panel. OpGen's Unyvero Urinary Tract Infection, UTI, Panel tests for a broad range of pathogens as well as antimicrobial resistance markers directly from native urine specimens. The clinical performance evaluation, which aims at a subsequent submission to the U.S. Food and Drug Administration, includes a prospective multicenter trial at three U.S. sites. OpGen recently added a fourth study site in the United States to optimize enrollment for different urine sample types to be included in the study. "The UTI trial completion and final data read out, which we expect in the second half of this year, will be another major milestone for OpGen" commented Oliver Schacht, CEO of OpGen. "Unblinding data from a major clinical trial is always an exciting catalyst, and we believe there is a clear unmet medical need for a rapid, comprehensive, sample to answer test for complicated urinary tract infections".

07:34 EDT Mindset Pharma, CAMH enter collaboration to build molecular profile of MSP-1014 - Mindset Pharma has entered into a research collaboration with the Centre for Addiction and Mental Health a top psychiatric research hospital based in Toronto, Canada. Mindset will sponsor a preclinical study at CAMH on its lead asset, MSP-1014, a novel and patented second generation psilocybin-like compound that is being prepared for First-in-Human studies alongside psilocybin. Single psychedelic experiences can cause both short- and long-term behavioral changes in humans and the mechanisms of these are relatively under explored. The study will interrogate how macro and micro doses of psychedelic compounds modulate expression levels of molecular biomarkers of brain plasticity in rats. The team expects to uncover short- and long-term changes in cFOS and BDNF expression that could underlie the long-term behavioral changes associated with a single psychedelic experience and develop molecular insights into the magnitude of effects of its lead compound, MSP-1014, compared to psilocybin. Dr. Anh Dzung Le, Senior Scientist and Head of Neurobiology of Alcohol Lab in the Campbell Family Mental Health Research Institute at CAMH, will lead the study, supported by Dr. Douglas Funk, a Project Scientist in the CAMH Neurobiology of Alcohol Lab

07:33 EDT Hudbay Minerals announces completion of mining activities at 777 mine - Hudbay Minerals announced that mining activities at the company's 777 mine in Flin Flon, Manitoba, have concluded after the reserves were depleted following 18 years of steady production. Closure activities at the 777 mine have commenced and employees and equipment are transitioning to the company's operations in Snow Lake, Manitoba. The 777 deposit was a large and rich orebody and for many years was the flagship mine of Hudbay's Manitoba operations. The mine commenced production in 2004 with an initial ten-year mine life, operated steadily and successfully expanded reserves by an additional eight years. After extensive drilling in and around the mine in recent years, no new deposits were identified and the 777 mine hoisted its last skip of ore late last week. The company's hydrometallurgical zinc facility in Flin Flon will also be closed after more than 25 years of successful operations. The 777 mine and the zinc plant are scheduled to be safely decommissioned by September 2022. The Flin Flon concentrator and tailings impoundment area will be shifted to care and maintenance, which could provide optionality should another mineral discovery occur in the Flin Flon area. Hudbay strives to achieve the highest closure practices and has considered stringent and detailed environmental plans to manage water and the remaining infrastructure and processing plants in Flin Flon. Personnel and equipment are being deployed from 777 to Hudbay's Lalor mine in Snow Lake as part of the Lalor ramp-up strategy. The Lalor mine is a meaningful low-cost gold producer that substantially benefited from the refurbishment of the New Britannia mill in 2021. Hudbay's Snow Lake operations have a 17-year mine life and are expected to produce over 180,000 ounces of gold annually at average cash costs, net of by-product credits, of $412 per ounce over the next six years.

07:31 EDT iKena Oncology receives FDA Fast Track designation for IK-930 - Ikena Oncology announced that the U.S. Food and Drug Administration has granted Fast Track designation for IK-930, the Company's novel TEAD inhibitor targeting the Hippo signaling pathway, in patients with unresectable NF2-deficient malignant pleural mesothelioma. IK-930 is currently being studied in a Phase 1 clinical trial as a monotherapy in patients with advanced solid tumors with or without gene alterations in the Hippo pathway, including NF2-deficient malignant mesothelioma, Epithelial Hemangioendothelioma with documented TAZ/CAMTA1 fusion genes as well as other solid tumors with either NF2 deficiency or with YAP/TAZ genetic fusions. Preclinical and translational data shared at the American Association for Cancer Research 2022 Annual Meeting highlighted IK-930 as a potential first-in-class TEAD inhibitor that could address unmet need and overcome therapeutic resistance.

07:30 EDT Ocean Bio Chem trading halted, news pending

07:26 EDT Aclarion to present two-year follow up data on Nociscan clinical trial - Aclarion announced today that the Company will be participating in the 17th Annual State of Spine Surgery Think Tank in Los Cabos, Mexico, June 22-25, 2022, where it will be presenting 2-year follow up data on its pivotal clinical trial published in the European Spine Journal in 2019. The company will also outline its schedule for release of an economic analysis report and initiation of future clinical studies aimed at establishing Nociscan as a standard of care for chronic low back pain. Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology leverages magnetic resonance spectroscopy and proprietary algorithms to identify and analyze chemical biomarkers in the discs demonstrated to be associated with pain. When used with other diagnostic tools, the Aclarion solution provides critical insights into the location of the patient's lower back pain, giving physicians clarity to optimize treatment strategies. On Friday, June 24th, Nociscan will be showcased in a presentation titled, "Aclarion: Resolving the Discogenic Low Back Pain Dilemma," to be presented by Robert Eastlack, MD, Division Head, Spine Surgery, Scripps Clinic Medical Group. In a paper published in the European Spine Journal in 2019, 97% of patients who had surgical intervention for chronic discogenic low back pain met the criteria for significant clinical improvement at one year follow up if all the discs identified as painful by Nociscan were included in the patient's surgical treatment. This compared to only 54% of patients meeting the criteria for success when a painful disc identified by Nociscan was excluded from treatment or a nonpainful disc was included in treatment. After two years of follow up, these results are proving to be durable with 87% of patients who had surgery at all discs identified as painful by Nociscan continuing to show significant clinical improvement. As part of the presentation, Dr. Eastlack will also outline the schedule of clinical trials Aclarion will be initiating this year to build upon the existing body of evidence supporting the efficacy of Nociscan. Aclarion is using recent IPO funding to focus on securing favorable coverage decisions from payers. This includes utilizing existing peer-reviewed publications and clinical results to pursue immediate coverage decisions for Nociscan, a non-invasive and objective diagnostic, as an alternative to discogram, an invasive procedure that is painful by design. The Company is already engaging payers for these coverage decisions and will report on favorable results as they develop. In addition, the Company is pursuing an aggressive clinical strategy to become standard of care for the treatment of low back pain. This clinical strategy includes not only CLARITY, but additional clinical studies called BACPAC BEST and BOND. The Company will report on the initiation of each of these studies as they launch in 2022.

07:23 EDT Next Hydrogen Solutions announces results of annual general meeting - Next Hydrogen Solutions announced the results of the annual general and special meeting of shareholders held on June 21, 2022. All matters presented for approval at the Meeting have been fully authorized and approved. A total of 9,553,950 common shares, representing 41.74% of the common shares issued and outstanding, were represented in person or by proxy at the meeting. The ordinary resolution to approve fixing the number of directors to be elected at the meeting at eight was approved at the meeting by way of electronic ballot. All of the nominees proposed as directors of the Corporation were duly elected as directors of the Corporation with votes cast by the shareholders present in person or represented by proxy at the meeting by way of electronic ballot. An ordinary resolution to approve the appointment of KPMG LLP, as the auditors of the Corporation, was approved at the meeting by way of electronic ballot. An ordinary resolution to approve the equity incentive plan for the Corporation, as more particularly set out in the management information circular dated May 10, 2022, was approved at the meeting by way of electronic ballot.

07:20 EDT Xos set to join Russell 3000 Index - Xos will join the broad-market Russell 3000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022.

07:18 EDT OTC Markets Group welcomes Yellow Cake to OTCQX - OTC Markets Group announced Yellow Cake has qualified to trade on the OTCQX Best Market. Yellow Cake plc upgraded to OTCQX from the Pink market.

07:15 EDT uniQure announces grant equity awards to 32 new employees - uniQure announced that the Company granted equity awards to 32 newly hired employees as a material inducement to commencing their employment. The equity grants were approved on April 29, 2022 in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the employees received 84,900 restricted stock units, RSUs, and options to purchase 119,000 ordinary shares of uniQure. Each option has an exercise price of $14.94 per share, the closing price per ordinary share as reported by Nasdaq on the Grant Date. Each option has a ten-year term and will vest over four years from the Grant Date, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and an additional 6.25% of the shares vesting in approximately equal quarterly installments over the twelve successive quarters following the first anniversary of the Grant Date. The RSUs will vest over three years, with one-third of the RSUs vesting annually on each successive anniversary of the Grant Date.

07:13 EDT Cyclacel Pharmaceuticals announces Ferguson elected to board of directors - Cyclacel Pharmaceuticals announced the election of Kenneth Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders. Dr. Ferguson's professional experience includes over 30 years of scientific and drug development experience in the biopharmaceutical industry. Currently, he serves as an Operating Partner at Accelerator Life Science Partners.

07:12 EDT BioCryst announces ORLADEYO data to be presented at EEACI Hybrid Congress 2022 - BioCryst Pharmaceuticals announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology, EAACI, Hybrid Congress 2022 from July 1-3, 2022, at the O2 universum in Prague, Czech Republic. Details of the three abstracts that will be presented in Flash Talks sessions include:"Attack-free Status in Patients who Switched from Subcutaneous Lanadelumab to Oral Berotralstat; Abstract #311;" "Improvement in Quality of Life and Hereditary Angioedema (HAE) Attack Rates Observed in Patients Treated with Long-term Berotralstat in the APeX-2 Study;" "96 Weeks of Treatment with Berotralstat Consistently Decreases the Use of Injectable On-Demand Medication to Treat Hereditary Angioedema (HAE) Attacks: Analysis from APeX-2."

07:11 EDT Medicenna Therapeutics announces expected upcoming milestones - Initial PK/PD data from the fourth dose escalation cohort of the Phase 1/2 ABILITY study expected in July 2022. Identification of MDNA11's recommended Phase 2 dose (RP2D) in the ABILITY study expected in the fourth quarter of calendar 2022. Commencement of the ABILITY study's single agent expansion phase expected in the fourth quarter of calendar 2022. Clinical update from the ABILITY study expected in the fourth quarter of calendar 2022.

07:09 EDT Digihost completes acquisition of 55 MW site in Alabama - Digihost Technology announces that it has completed its previously announced transaction with Grede II to acquire property in the state of Alabama in order to expand the Company's current operational capacity. The total cash consideration paid for the property by the Company was $1.5M, with an additional $1.25M to be paid in 25 equal monthly installments of $50,000 per month. "The successful acquisition of our new site in Alabama marks a significant milestone in Digihost's history, firmly establishing the Company as a leading Bitcoin mining platform operating with jurisdictional diversification," said Michel Amar, Chairman and CEO of Digihost. "With Digihost's capability to build out the existing infrastructure in place at the property and implement best-in-class construction, development, and operational excellence, the Company is well-positioned to increase the scale and scope of its operations with this new site while utilizing clean and renewable energy sources in the process." Digihost plans to immediately commence construction and the development of the facilities in Alabama with the goal of bringing the property to a hashing capacity of 28 MW by the end of the third quarter of 2022 and a total of 55 MW by the end of the first quarter of 2023.

07:08 EDT Winnebago expects supply chain inconsistencies to continue in Q4, 2023 - CEO Michael Happe continued, "Looking at the broader economic trends, we have been successful in managing supply chain disruptions, improving dealer inventory levels, navigating cost inflation, and driving manufacturing productivity to deliver consistently strong results. We expect supply chain inconsistencies and inflation pressures to continue in the fourth quarter, and into our fiscal 2023, and we are focused on continuing to stay ahead of them by leveraging our resilient operating structure, deep and collaborative relationships with our dealers and suppliers, and highly-differentiated, premium portfolio of brands. We are confident that the continued execution of our strategy, including a focus on innovation and a differentiated product and overall customer experience, and unwavering commitment to our team and communities positions Winnebago Industries for sustained market share gains and strong profitability across our business."

07:06 EDT Guardforce AI expands RaaS business offering in Japan, US - Guardforce AI announced that it has opened new offices in Tokyo, Japan and San Francisco, California, expanding its Robotics-as-a-Service, RaaS, business lines in these two markets. The Company's robotics solutions offering in these two locations will include the T-series robot for reception services, food delivery robots, and disinfection robots for restaurants, shopping malls and hotels. Terence Yap, Chairman of Guardforce AI, commented, "Opening offices in Tokyo and San Francisco mark important milestones as these two markets represent significant opportunities for our RaaS business line. With increasing labor costs and the aging population, in Japan alone automated robotic services are expected to double from 2020 to 2026. In addition, San Francisco is a well-known tech hub with high quality technology engineers and renowned technology research centers, making it the perfect location to set up our RaaS operations to attract talent and build a comprehensive technology ecosystem surrounding our RaaS solutions. We are rapidly expanding in key markets globally to meet the growing needs of our clients and partners with the goal of becoming a leading provider of RaaS services worldwide."

07:06 EDT Rezolve enters strategic partnership with ACI Worldwide - Rezolve and ACI Worldwide announced a strategic partnership that will see Rezolve's technology integrated into the ACI Omni-Commerce solution, a secure omni-channel payment processing platform with the flexibility to support the in-store, online and mobile needs of consumers. The technology integration will also include ACI Secure eCommerce, a holistic platform that combines a powerful payments gateway, sophisticated real-time fraud prevention capabilities and advanced business intelligence tools. With ACI Secure eCommerce, Rezolve will have a single platform to quickly onboard customers in new geographies and address future payments evolution and challenges.

07:04 EDT Evoqua Water to acquire Smith Engineering - Evoqua Water announced that it has entered into a definitive agreement to acquire privately-held Smith Engineering. The acquisition will enhance Evoqua's portfolio of high purity water treatment systems and expand its service footprint in North America. Smith Engineering is headquartered in Chaska, Minnesota. With over 1,200 customers in North America, Smith Engineering offers a variety of water treatment products and services, including filtration, UV, reverse osmosis, and deionization. The transaction is expected to close during Evoqua's fourth quarter of FY22, which ends September 30, subject to the satisfaction of customary closing conditions. Upon closing the transaction, the business will be part of Evoqua's Integrated Solutions and Services segment.

07:04 EDT OneWater Marine to acquire Ocean Bio-Chem for $13.08 per share in cash - OneWater Marine (ONEW) announced that it has signed a definitive agreement to acquire Ocean Bio-Chem, Inc. (OBCI) for $13.08 per share, in an all-cash transaction valued at approximately $125 million. As part of the transaction, OneWater will also acquire OBCI's affiliate, Star Brite Europe, Inc. Upon closing of the transaction, both OBCI and Star Brite Europe, Inc. will be integrated into T-H Marine Supplies, LLC, OneWater's subsidiary and strategic growth platform for parts and accessories businesses. As a vertically integrated supplier, OBCI manufactures, markets, and distributes a broad line of products under Star brite, Star Tron, Odor Star, Performacide, and other brand names. In addition, OBCI provides private label production, blending, and packaging for many of its products. Ocean Bio-Chem's headquarters are located in Ft. Lauderdale, FL with a manufacturing plant in Montgomery, AL, shipping products globally. Ocean Bio-Chem's Board of Directors, based on the recommendation of a special committee of disinterested directors formed by the Board to evaluate the transaction, has unanimously approved the transaction. OneWater will finance the transaction with an extension of its term loan facility led by Truist Bank and has received a commitment letter to be executed following the transaction closing. The transaction is expected to close during the Company's fiscal fourth quarter 2022, which ends September 30, 2022, and is subject to usual and customary closing conditions as well as regulatory review and approval.

07:03 EDT Ford selects Valencia plant for next-gen EV assembly - Ford in Europe confirmed that it has chosen its plant in Valencia, Spain, as the preferred site to assemble vehicles based on a next-generation electric vehicle architecture. "Pending product approval, the Valencia plant could produce breakthrough electric and connected vehicles beginning later this decade. Ford is also moving forward with a $2 billion conversion of its Cologne, Germany, operations to begin producing electric passenger vehicles starting in 2023. Ford's European strategy calls for an exciting line-up of electric vehicles, including an electric version of the popular Ford Puma and extending its leadership in the commercial segment with electric Ford Pro vehicles and connected services. By 2026, Ford in Europe plans to sell 600,000 electric vehicles annually," the company stated. Reference Link

07:02 EDT Bio-Techne to acquire Namocell - Bio-Techne has reached an agreement to acquire Namocell. Bio-Techne anticipates the acquisition to close in Q1 of FY23. Founded in 2014 and headquartered in Mountain View, California, Namocell is a provider of single cell sorting and dispensing platforms that preserve cell viability and integrity. Namocell's current installed base is approaching 200 placements, including approximately 60 instruments sold in calendar 2021.

07:01 EDT Valens signs exclusive cannabis partnership with Coldhaus Distribution - The Valens Company announced that it has secured an exclusive cannabis partnership with Coldhaus Distribution to provide integrated logistics solutions for Valens-branded cannabis products across Ontario, Alberta, and British Columbia. Pursuant to the two-year partnership, Coldhaus in conjunction with Valens will be responsible for store level representation, brand advocacy, distribution route coverage and retail staff education to drive brand visibility and commercial retail presence. Furthermore, leveraging Coldhaus' direct-to-store management infrastructure we believe will significantly increase the frequency, reach and touchpoints of our brands as we continue to penetrate key retail relationships. The dedicated field team to be put in place through this partnership will allow Valens to connect with and educate retail staff in respect to our brands and product attributes providing a unique opportunity to help drive consistent in-store category strategy while supporting retailers as they focus on enriching consumer experience.

06:56 EDT Takeda Pharmaceutical announces creation of R&D center in Kendall Square - Takeda announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded technology to support the company in its efforts to advance innovation for patients. The new facility will support Takeda's efforts to redefine the future of work by adopting flexible workspaces to maximize in-person interaction and connection under a flexible and hybrid working model. The company will also expand its existing space in 650 East Kendall to include two additional floors, making Takeda the sole laboratory and office tenant in that building.

06:53 EDT Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer - Owens & Minor (OMI) announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11. Gomez will report to Owens & Minor's President and CEO, Edward Pesicka, and be a member of the company's executive leadership team. Gomez brings more than two decades of healthcare industry experience to Owens & Minor, having held leadership positions of increasing responsibility over the course of her career, most recently as SVP, Global Human Resources Centers of Excellence & Human Resources Services and Solutions for Cardinal Health (CAH).

06:48 EDT Merck announces FDA approves expanded indication for VAXNEUVANCE - Merck announced that the U.S. FDA has approved an expanded indication for VAXNEUVANCE to include children 6 weeks through 17 years of age. VAXNEUVANCE is now indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older. The approval follows the FDA's Priority Review of Merck's supplemental application. VAXNEUVANCE is contraindicated for individuals with a severe allergic reaction to any component of VAXNEUVANCE or to diphtheria toxoid.

06:30 EDT Novo Nordisk, Echosens announce partnership to increase early diagnosis of NASH - Echosens and Novo Nordisk A/S announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis, or NASH, and increase awareness of the disease among patients, healthcare providers and other stakeholders. Echosens and Novo Nordisk will collaborate to support additional clinical validation, generation of real-world evidence and adoption of non-invasive diagnostic tests for NASH and work together to increase awareness of the disease and the importance of early diagnosis and management. The companies have a shared ambition of doubling diagnostic rates for people living with advanced to severe NASH by 2025.

06:08 EDT Amazon names Doug Herrington as CEO of Worldwide Amazon Stores - Amazon CEO, Andy Jassy, said in a message to employees on Tuesday: "I'm excited to share that Doug Herrington will become the new CEO of our Worldwide Amazon Stores business. Doug has been at Amazon for 17 years. He joined the company in 2005 to build out our Consumables business, launched AmazonFresh in 2007, and in 2015, took on leading all of our North American Consumer business... As part of this organizational change, Doug and I are pleased to share that the Operations organization will be united under a single leader, John Felton... This is a very strong and experienced leadership team. I remain very optimistic about our Stores business, and believe we're still in the early days of what's possible."

06:05 EDT Vaccitech's VTP-300 shows efficacy in hepatitis B study - Vaccitech updated the interim analysis of safety and efficacy data from the HBV002 study being presented as a poster at the 2022 EASL International Liver Congress. The updated analysis, which now includes 39 patients with at least three months of follow-up, shows that VTP-300 as a monotherapy or in combination with a single low-dose nivolumab at the time of the booster dose was safely administered with no treatment-related serious adverse events and two patients with mild, rapidly resolving transaminitis. In the VTP-300 monotherapy group, meaningful and durable reductions of Hepatitis B surface antigen, or HBsAg, were seen in all three patients with baseline HBsAg under 50 IU/mL. These dramatic declines have persisted in all three patients at their latest follow-up at five or eight months after the last dose of VTP-300. For the first eight patients who received VTP-300 in combination with a single low-dose of nivolumab at the time of the booster dose, the mean reduction in HBsAg was over 1 log10 at six months, an effect that persisted. A robust T cell response against all encoded antigens was observed following VTP-300 administration. Enrollment in the HBV002 study is complete with 55 patients enrolled. An updated interim analysis for all patients at the six month follow-up timepoint is expected at the end of 2022. A trial to look at timing of low dose nivolumab and additional doses of the MVA boost component of VTP-300 is planned in multiple countries, with the first patient expected to be dosed in Q3.

05:24 EDT Roxe to become public through Goldenstone Acquisition merger agreement - Goldenstone Acquisition announced that it has entered into a definitive merger agreement with Roxe, a blockchain-based payments company that is powering the next generation of payment solutions, that will result in Roxe becoming a publicly traded company on the Nasdaq Stock Market. The transaction is subject to approval by Goldenstone and Roxe stockholders and other closing conditions, including regulatory approvals. Roxe is on a mission to build a global trusted community that includes everyone: individuals, banks, central banks, non-bank financial institutions, businesses, and merchants. Its blockchain offers a multilateral payment channel that supports multiple assets including currency, gift cards, gaming coins, loyalty rewards, stocks, cryptocurrencies, and CBDC. To date, 44 global partners use Roxe's global payment community, including ECS Fin, Axletree Solutions, Nium, N2Xpress, Fairexpay, Rana Express, iPay, and Treviso. These partners enable their B2C and B2B customers to send and receive payments from 113 countries around the world. Under the terms of transaction, Roxe will merge with a wholly owned subsidiary of Goldenstone. In connection with the closing of the transaction, Goldenstone will be renamed as Roxe. The pro forma combined enterprise value at signing is approximately $3.6B, subject to adjustment based on a valuation being conducted by an independent investment bank. It is anticipated that Roxe stockholders will roll 100% of their equity into the combined company and certain stockholders will have the potential to receive an earnout for additional shares of equity if certain price targets are met as set forth in the merger agreement. The transaction is expected to close during Q1 of 2023 and remains subject to approval by Goldenstone's and Roxe's stockholders, the effectiveness of a registration statement to be filed with the Securities and Exchange Commission in connection with the transaction, and other customary closing conditions.

05:13 EDT NaaS Technology enters EV partnership with State Grid Changzhi Electric Power - NaaS Technology Inc. entered into a strategic partnership with State Grid Changzhi Electric Power Supply to build new electric vehicle, or EV, charging stations in a move to enhance the local charging services in Changzhi, Shanxi Province. Senior executives from both parties attended the ceremony, including Yu Xiang, VP of operations, NaaS, and Hao Xiangjun, Deputy General Manager of State Grid Changzhi Electric Power Supply Company. Under the agreement, State Grid Changzhi Electric Power Supply Company will provide construction sites and a stable power supply for new EV charging stations, while NaaS will build and operate the charging facilities, providing services including site selection, construction, and operation and maintenance, or O&M. The company will also provide charging pile operators with online and offline services including customer sourcing, marketing, O&M and facilities cleaning, alongside the provision of onsite food outlets as well as aftermarket and other value-added services - all as part of the city's overall plan to increase the utilization of charging piles and to build a charging services ecosystem.

05:07 EDT Cazoo launches in Italy - Cazoo announced that it has launched in Italy, delivering better selection, value, transparency, convenience and peace of mind to Italian consumers when buying their next car.